Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.
2.

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

Freeman HL.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S11-7. Review.

PMID:
9218163
3.

Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?

Blin O.

Encephale. 2000 Oct;26 Spec No 1:7-11. Review. English, French.

PMID:
11294060
4.

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

Colonna L, Saleem P, Dondey-Nouvel L, Rein W.

Int Clin Psychopharmacol. 2000 Jan;15(1):13-22.

PMID:
10836281
5.
6.

Amisulpride: progress and outcomes.

Lecrubier Y.

Curr Med Res Opin. 2002;18 Suppl 3:s18-22. Review.

PMID:
12418608
7.

[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].

Chabannes JP, Pelissolo A, Farah S, Gerard D.

Encephale. 1998 Jul-Aug;24(4):386-92. French.

PMID:
9809244
8.

Clinical update on amisulpride in deficit schizophrenia.

Rein W, Turjanski S.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S19-27. Review.

PMID:
9218164
9.

[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].

Pélissolo A, Krebs MO, Olié JP.

Encephale. 1996 May-Jun;22(3):215-9. Review. French.

PMID:
8767050
10.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
11.

Clinical advantages of amisulpride in the treatment of acute schizophrenia.

Burns T, Bale R.

J Int Med Res. 2001 Nov-Dec;29(6):451-66.

PMID:
11803729
12.

Amisulpride: a review of its use in the management of schizophrenia.

McKeage K, Plosker GL.

CNS Drugs. 2004;18(13):933-56. Review.

PMID:
15521794
13.

A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.

Riedel M, Eich FX, Möller HJ.

Eur Psychiatry. 2009 Apr;24(3):149-53. doi: 10.1016/j.eurpsy.2008.10.005.

PMID:
19070995
14.

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.

Delcker A, Schoon ML, Oczkowski B, Gaertner HJ.

Pharmacopsychiatry. 1990 May;23(3):125-30.

PMID:
1973843
15.

Safety of amisulpride (Solian): a review of 11 clinical studies.

Coulouvrat C, Dondey-Nouvel L.

Int Clin Psychopharmacol. 1999 Jul;14(4):209-18.

PMID:
10468313
16.

Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.

Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O; Amisulpride Study Group..

J Clin Psychopharmacol. 2002 Dec;22(6):554-60.

PMID:
12454554
17.

Safety profile of amisulpride in short- and long-term use.

Rein W, Coulouvrat C, Dondey-Nouvel L.

Acta Psychiatr Scand Suppl. 2000;400:23-7. Review.

PMID:
10823308
18.

Amisulpride: a review of its efficacy in schizophrenia.

Möller HJ.

Acta Psychiatr Scand Suppl. 2000;400:17-22. Review.

PMID:
10823307
19.

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.

Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O.

Br J Psychiatry. 1997 Jan;170:18-22.

PMID:
9068769
20.

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.

Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G.

Pharmacopsychiatry. 2008 Jan;41(1):24-8. doi: 10.1055/s-2007-993209.

PMID:
18203048
Items per page

Supplemental Content

Support Center